Bausch + Lomb to Highlight Real-World Product Data and Unveil Survey Results on Dry Eye Disease in Europe and the Middle East at the European Dry Eye Congress

VAUGHAN, Ontario, June 17, 2025 – Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will  present seven posters at the European Dry Eye Congress (EuDEC) in Krakow, Poland, June 19–21, including results of a multinational survey1 on the prevalence, impact and treatment of dry eye in Europe and the Middle East.

“Dry eye is a global phenomenon, but most data is specific to the U.S.,” said Yehia Hashad, MD, chief medical officer and executive vice president, Research & Development, Bausch + Lomb. “We commissioned this study to fill gaps in the understanding of how dry eye is experienced around the world.”

Key findings from the survey (average across five countries —France, Germany, Poland, Saudi Arabia and the UK):

  • 58% of adult dry eye sufferers experience frequent or occasional symptoms, but only 1 in 5 have been diagnosed.
  • 60% of sufferers waited at least four months before seeking help from an eyecare provider.
  • Up to one third of dry eye sufferers have been experiencing symptoms for over 5 years.
  • Many sufferers had stopped driving at night (17%), no longer wear makeup (14.8%) or have reduced their use of heat or air conditioning (15.2%) due to their uncontrolled dry eye symptoms.
  • Approximately 1 in 3 dry eye sufferers reported symptoms that became more bothersome in the past year, while relatively few patients indicated that their symptoms improved.

Additional study results will be included in a EuDEC presentation by Marc Labetoulle, MD, et al.

Please see below for information on Bausch + Lomb activities at EuDEC. Bausch + Lomb can be found at booth #1.

Industry Innovation Session
Bausch + Lomb Innovation: Advancing Ophthalmic Breakthroughs Together

  • This session will highlight Bausch + Lomb’s latest advances across its pipeline, with a focus on translating scientific innovation into meaningful outcomes for patients and eye care professionals worldwide.
  • Friday, June 20 at 16:30–17:30 CET
  • Presenter: Mohamed Yassine, MD, vice president, Global Medical & Scientific Affairs, Bausch + Lomb

Symposium
A Drop of Science: Refining Formulations for Dry Eye Through Better Understanding

  • This symposium will examine unmet needs in dry eye and the science behind the condition. Experts will also discuss artificial tear formulations that aim to help address patient challenges.
  • Saturday, June 21 at 14:45–15:30 CET
  • Speakers: Elisabeth Messmer, MD, PhD; José Benítez de Castillo MD, PhD; Omür Uçakhan-Gündüz, MD

Oral Presentation
Needs Unmet in Dry Eye: Symptoms, Treatment and Severity (NESTS) Study – Analysis from a Multinational Survey

  • This presentation will share key insights from the NESTS study, highlighting significant gaps in symptom management, treatment satisfaction, and disease burden in patients with dry eye across multiple countries
  • Saturday, June 21 at 8:00–8:30 CET
  • Presenter: Marc Labetoulle, MD, Le Kremlin-Bicêtre, France

Poster Presentations

  • “Dry Eye Symptoms, Severity, Treatment and Unmet Needs: An Analysis from Multinational Survey.” Labetoulle M, et al.
  • “Retrospective Real-World Evidence Study: Utilization Patterns and Real-World Clinical Outcomes with Artelac* Ultra 4s Dry Eye Lubricating Drops in Patients with Dry Eye Disease.” Benítez del Castillo JM, et al.
  • “Real-World Clinical Experience with Dry Eye Lubricating Drops: Utilization Patterns, Outcomes and Healthcare Provider Satisfaction.” Uçakhan-Gündüz O, et al.
  • “Impact of Lipid Components on Patient Symptoms: Results from a Multicentre Clinical Study of Two Preservative-Free Artificial Tears with Sodium Hyaluronate.” Labetoulle M, et al.
  • “Retrospective Real-World Evidence Study: Utilization Patterns and Real-World Clinical Outcomes with Artelac* Complete Dry Eye Lubricating Drops in Patients with Dry Eye Disease.” Boboridis K, et al.
  • “Evaluation of the Efficacy of an Ectoin-Containing Ophthalmic Solution Compared with Hyaluronic Acid Eye Drops in the Treatment of Dry Eye Disease as Assessed by Tear Break-Up Time.” Messmer E, et al.
  • “Evaluation of the Efficacy of an Ectoin-Containing Ophthalmic Solution Compared with Hyaluronic Acid Eye Drops in the Treatment of Dry Eye Disease: Patient-Reported Outcomes.” Uçakhan-Gündüz O, et al.

* Artelac® eye drops are not available in the United States.

###

About the Survey
The 2025 International Study of Dry Eye Sufferers covered five markets – France, Germany, Poland, Saudi Arabia and the UK – and was conducted in two phases. Phase I consisted of 2,580 online interviews conducted in February and March 2025 with national samples of adults aged 18 and older in each country. Phase 2 involved online surveys conducted in March and April 2025 with 2,572 adults, aged 18 or older who reported experiencing dry eye symptoms regularly.

About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on Facebook , Instagram , LinkedIn , X and YouTube .

 References

  1. The 2025 International Study of Dry Eye Sufferers. Multi-sponsor Surveys, Inc. April 2025.

Media Contact:
Caryn Marshall
[email protected]
(908) 493-1381

© 2025 Bausch + Lomb.

Back to Press Releases